Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAB-22 vs Prolia in Postmenopausal Women with Osteoporosis
2024-512417-41-00Phase 3Completed
- Sponsor
- Xentria
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in osteoporosis comparing MAB-22 with Prolia (2 arms). Primary endpoints: Percentage change from baseline in lumbar spine BMD at Week 52 and AUEC of sCTX over initial 6 months. Started Sep 2024; status: completed.
02
Drugs
INTP23denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2024-512417-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512417-41-00.